USAMRIID | GenomeWeb

USAMRIID

US Army scientists have developed a way to more precisely determine the amount of antigen needed as they develop an Ebola virus-like particle vaccine.

Ebola virus genomes from a post-epidemic flare-up last June showed relatively low genetic divergence compared with related strains from the broader outbreak.

Using new and existing Ebola virus genomes, researchers retraced transmission events involved in the second wave of infections in Liberia.

New research suggests Ebola virus may appear in survivor sperm samples some nine months after disease onset, though sexual transmission appears relatively rare. 

A new study has found that an antigen-based rapid diagnostic test for Ebola could be more reliable under certain circumstances than a recently approved RT-PCR assay for the virus.

Researchers sequenced 25 Ebola genomes isolated from patients infected during the outbreak, publishing their results in Emerging Infectious Diseases

The team tracked down several hundred SNPs in the Ebola genome, including mutations that could alter the effectiveness of treatments targeting certain virus sequences.

NEW YORK (GenomeWeb) — Luminex said today that the US Army Medical Research Institute of Infectious Diseases (USAMRIID) is using Luminex's xMAP technology to develop rapid diagnostics for the Ebola virus.

NEW YORK (GenomeWeb) – An American team led by researchers at the US Army Medical Research Institute of Infectious Diseases (USAMRIID) has come up with a proposed set of standards for investigators sequencing and assembling viral genomes.

ZyGem said today that it has signed a cooperative research and development agreement with the US Army Medical Research Institute of Infectious Diseases to develop simplified sample processing tools for biothreat agent detection.

Pages

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.